Bortezomib is safe in and stabilizes pulmonary function in patients with allo-HSCT-associated pulmonary CGVHD. [electronic resource]
Producer: 20190925Description: 1124-1130 p. digitalISSN:- 1476-5365
- Adolescent
- Adult
- Aged
- Bortezomib -- therapeutic use
- Female
- Graft vs Host Disease -- drug therapy
- Hematopoietic Stem Cell Transplantation -- adverse effects
- Humans
- Lung Diseases -- drug therapy
- Male
- Middle Aged
- Multiple Myeloma -- therapy
- Pilot Projects
- Respiratory Function Tests
- Treatment Outcome
- Young Adult
No physical items for this record
Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.